TORONTO, May 28, 2013 /CNW/ -The following B-Roll is available by Video
On-Demand web download:

STORY SUMMARY: Canadian-led research into the human microbiome—otherwise known as the
'gut'—has led to the discovery of a new, natural approach for
cholesterol management. Cardioviva is a probiotic supplement that is
clinically proven to reduce LDL ("bad") cholesterol and help maintain
healthy cholesterol levels in adults. It comes at a time when 40% of
Canadians have high blood cholesterol, a risk factor for heart disease.
Currently, scientific and public health leaders around the world are
putting significant effort into better understanding the microbiome,
and Cardioviva represents a Canadian breakthrough in this field while
illustrating an important new role for probiotics. Cardioviva is the
first probiotic supplement that's been shown to move a recognized
marker for disease (cholesterol), and it brings to light the fact that
gut health can contribute to heart health.

Speakers

Dr. Mitchell Jones: Microbiome expert and Cardioviva CSO

Ryan Jones: Cardioviva CEO

Dr. Chris Mohr: Nutrition Expert

SHOT LIST: Inside the Cardioviva lab (Montreal): research equipment; Dr. Mitchell
Jones at work with research team; Cardioviva bacteria strain (closeup);
Dr. Mitchell Jones and Ryan Jones of Cardioviva; visuals from news
conference/announcement at MaRS Discovery District in Toronto.